Dual inhibition of IL-4 and IL-13 with dupilumab represents a very promising avenue for biologic-based asthma therapy, but further large-scale clinical trials on patients with day-to-day asthma ...

A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy ... now backing up those results in ...